Moderna's updated Spikevax shot includes 25 µg of spike protein mRNA from BA.4/BA.5 and 25 µg from the original strain of SARS-CoV-2, and has been authorised for the over-18s. It has also been ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

Sometimes called the “great pause,” the COVID-19 pandemic began in late December 2019 in Wuhan, China. One month later, on Jan. 30, 2020, the World Health Organization (WHO) declared it a ...

During the pandemic,COVID-19 killed more than 7 million people worldwide, including 1.2 million in the U.S. and more than ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

In part B, the researchers noted that baseline GMTs and day 29 geometric mean fold-rises for nAbs against RSV-A, RSV-B, and SARS-CoV-2 (ancestral and Omicron) were generally ... This study was ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock.

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Tuesday ...